<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02451163</url>
  </required_header>
  <id_info>
    <org_study_id>Fib-CC-2014</org_study_id>
    <nct_id>NCT02451163</nct_id>
  </id_info>
  <brief_title>DBRCT on the Effect of Wheat Polysaccharides on Common Cold Infections in Elderly</brief_title>
  <acronym>Fib-CC-2014</acronym>
  <official_title>A Randomized, Controlled Clinical Study on the Effect of Polysaccharides From Wheat on Common Cold Infections in Elderly</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinical Research Center Kiel GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioActor</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Clinical Research Center Kiel GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to measure the effect of wheat polysaccharides on the occurence of
      common cold (CC) in elderly during a 12-week consumption period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is conducted in the frame of the collaborative project 'FibeBiotics' (No. 289517)
      (Fibers as support of the Gut and Immune function of Elderly - From polysaccharide compound
      to health Claim) within the Seventh Framework Programme (FP7) for Research and Technological
      Development of the European Union (EU).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of common cold (CC) based on Jackson et al. 1958 and physicians diagnosis</measure>
    <time_frame>12 weeks</time_frame>
    <description>Occurrence of common cold (= number of subjects affected by at least one common cold episode during intervention) according to self-reporting (questionnaire based on Jackson et al. 1958) and physicians diagnosis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative severity of common cold episodes</measure>
    <time_frame>12 weeks</time_frame>
    <description>Cumulative severity of common cold episodes (= sum of daily symptom scores acc. to Jackson et al. 1958).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">247</enrollment>
  <condition>Upper Respiratory Infections</condition>
  <condition>Common Cold</condition>
  <arm_group>
    <arm_group_label>polysaccharides from wheat</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>12.0 g powder containing 10.0 g active ingredient (wheat polysaccharides) as well as 2.0 g filling substance (maltodextrin) stirred in milk or filtered apple juice (200 ml each).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control product</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>12.0 g maltodextrin stirred in milk or filtered apple juice (200 ml each).</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>wheat polysaccharides</intervention_name>
    <description>Consumed once daily for 12 weeks.</description>
    <arm_group_label>polysaccharides from wheat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>maltodextrin</intervention_name>
    <description>Consumed once daily for 12 weeks.</description>
    <arm_group_label>control product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  men and postmenopausal women aged â‰¥ 50

          -  willingness to abstain as far as possible from food and supplements containing
             probiotics, prebiotic supplements, other fermented products, supplements containing
             vitamins and minerals as well as willingness to sustain a low dietary fibre diet for
             14 weeks

          -  written informed consent

        Exclusion Criteria:

          -  subjects currently enrolled in another clinical study

          -  subjects having finished another clinical study within the last 4 weeks before
             inclusion

          -  surgery or intervention requiring general anaesthesia within 2 months before the study

          -  current symptoms of common infectious diseases (CID) of the airways or other organ
             systems e.g. gastrointestinal tract

          -  history of allergic rhinitis, allergic asthma, anaphylactic shock, quincke edema, food
             allergy (type I allergy)

          -  allergy or hypersensitivity to any component of the test product (e. g. wheat, corn)

          -  known congenital, acquired or iatrogenic immunodeficiency (e.g. HIV, chemotherapy,
             immunosuppression)

          -  active autoimmune diseases

          -  severe chronic disease (COPD, respiratory insufficiency, cancer, IBD, malabsorption,
             malnutrition, chronic inflammatory diseases, severe renal, hepatic or cardiac
             diseases)

          -  known coeliac disease (gluten enteropathy)

          -  chronic systemic or chronic topical treatment likely to interfere with evaluation of
             the study parameters: antiallergic drugs, antibiotics, intestinal or respiratory
             antiseptics, anti-rheumatics, antiphlogistics (except aspirin or equivalent products
             preventing from aggregation of platelets or blood clotting) and steroids prescribed in
             chronic inflammatory diseases (in the last 4 weeks before inclusion)

          -  diabetes mellitus

          -  other chronic treatments likely to interfere with study outcome: e.g. laxatives, body
             weight management and/or medication

          -  chronic abdominal pain

          -  bowel movement less than 3 times per week

          -  subjects, who meet 2 or more Rome III criteria for constipation or who take laxatives
             on a regular basis

          -  vegetarian, vegan diet

          -  eating disorders (e.g. anorexia, bulimia)

          -  alcohol and drug abuse

          -  severe neurological, cognitive or psychiatric diseases

          -  subjects not understanding or speaking fluently German

          -  legal incapacity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christiane Laue, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Research Center Kiel GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Center (CRC) Kiel GmbH</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24118</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2015</study_first_submitted>
  <study_first_submitted_qc>May 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2015</study_first_posted>
  <last_update_submitted>April 11, 2016</last_update_submitted>
  <last_update_submitted_qc>April 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Common Cold</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

